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Abstract
Keratinocyte growth factor 1 (KGF-1) has proven useful in the treatment of pathologies associated with dermal adnexae,
liver, lung, and the gastrointestinal tract diseases. However, poor stability and short plasma half-life of the protein have
restricted its therapeutic applications. While it is possible to improve the stability and extend the circulating half-life of
recombinant human KGF-1 (rhKGF-1) using solution-phase PEGylation, such preparations have heterogeneous structures
and often low specific activities due to multiple and/or uncontrolled PEGylation. In the present study, a novel solid-phase
PEGylation strategy was employed to produce homogenous mono-PEGylated rhKGF-1. RhKGF-1 protein was immobilized
on a Heparin-Sepharose column and then a site-selective PEGylation reaction was carried out by a reductive alkylation at the
N-terminal amino acid of the protein. The mono-PEGylated rhKGF-1, which accounted for over 40% of the total rhKGF-1
used in the PEGylation reaction, was purified to homogeneity by SP Sepharose ion-exchange chromatography. Our
biophysical and biochemical studies demonstrated that the solid-phase PEGylation significantly enhanced the in vitro and in
vivo biostability without affecting the over all structure of the protein. Furthermore, pharmacokinetic analysis showed that
modified rhKGF-1 had considerably longer plasma half-life than its intact counterpart. Our cell-based analysis showed that,
similar to rhKGF-1, PEGylated rhKGF-1 induced proliferation in NIH 3T3 cells through the activation of MAPK/Erk pathway.
Notably, PEGylated rhKGF-1 exhibited a greater hepatoprotection against CCl4-induced injury in rats compared to rhKGF-1.
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Introduction
Keratinocyte growth factor 1 (KGF-1), also known as fibroblast
growth factor 7 (FGF-7), is a paracrine-acting mitogen produced
by cells of mesenchymal origin in response to pro-inflammatory
cytokines and steroid hormones [1,2,3,4]. KGF-1 is a heparin
binding growth factor that acts exclusively through a splicing
variant of FGF receptor 2, FGFR2-IIIb, which is expressed
predominantly by epithelial cells in the tongue, oral mucosa and
gastrointestinal tract as well as liver, lung and pancreas [5].
Functional assays in organ and cell cultures and in vivo analysis
show that KGF-1 is mitogenically active only on epithelial cells
derived from a variety of tissues [6,7] without any tumorigenic
effect. Since KGF-1 impacts proliferation and differentiation in
parenchymal epithelial cells of differentiated tissues, it has been
proposed for treatment of pathologies associated with dermal
adnexae, liver, lung, and the gastrointestinal tract diseases,
particularly wound healing in various tissues and organs [8,9].
Recombinant human KGF-1 (rhKGF-1) can significantly reduce
the duration and incidence of oral mucositis after intensive
chemotherapy and radiotherapy and autologous hematopoietic
stem-cell transplantation. RhKGF-1, therefore, seems a major
breakthrough in the management of patients receiving intensive
treatment for solid tumours and haematological malignancies.
This has led the Food and Drug Administration (FDA) to approve
rhKGF-1, also known as Palifermin, for the prevention of oral
mucositis of patients with haematological malignancies and
boosted the development of other mucosa-protective growth
factors, such as repifermin (KGF-2) and velafermin (FGF-20).
Therapeutic applications of rhKGF-1 have been restricted by its
low level of expression in various expression systems, poor stability
and a relatively short half-life in vivo [10]. The protein unfolds
around body temperature (,37uC) and the unfolded protein
aggregates rapidly [11,12]. Moreover, frequent administration
(daily) of rhKGF-1 often results in impaired homeostasis in vivo and
may cause severe adverse effects such as rash, erythema, edema,
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taste alteration [9]. Given these limiting factors, high priority
should be given to the development of strategies that could
significantly enhance the stability and circulating half-life of
rhKGF-1.
Approaches to improve the stability and pharmacokinetic
properties of therapeutic proteins include structural modification
and covalent conjugation of polyethylene glycol (PEGylation)
[13,14]. PEGylation of drugs and therapeutic proteins has become
one of the most mature, valid and widely used drug delivery
technologies ever developed. It has been previously reported that
PEG-conjugated therapeutic peptides/proteins exhibit clinical
properties superior to those of their corresponding unmodified
parental molecules [15,16,17]. PEGylation delays drug absorption
thereby reducing serious side-effects caused by acute peak drug
concentration, and also prolongs the half-life of drugs and
therefore improves patients’ compliance by greatly reducing the
frequency of drug injections [15]. PEGylation is a reaction
between functional groups of an activated PEG and those of
specific residues, such as lysine, cysteine and N-terminal residues,
in a protein structure [18]. Presence of several reactive amino
acids on a protein surface results in random non-site-specific
mono- and multiple-PEGylations, which in turn may mask or
interfere with receptor binding sites of PEGylated proteins and
may also lead to a dramatic reduction in their biological activities
[19]. Hence, a site-specific and well-controlled PEGylation might
be the attractive possibilities offering the advantages to retain
bioactivity of therapeutic proteins and to generate chemically
identical entities with predictable pharmaceutical behavior.
In the present study, for the first time, we propose solid-phase
PEGylation for a site-specific modification of rhKGF-1. Using this
novel PEGylation approach, we successfully modified the rhKGF-
1 at the N-terminal residue with 20 kDa mPEG-butyraldehyde
and produced a highly homogeneous mono-PEGylated rhKGF-1.
Our bioactivity and CD analysis data showed that solid-phase
PEGylation did not impinge on the activity and structure of
rhKGF-1. Furthermore, our in vitro and in vivo biostability analyses
showed that PEGylated rhKGF-1 was significantly more stable
than non-PEGylated rhKGF-1. Importantly, PEGylated rhKGF-1
was found to be significantly more effective than rhKGF-1 in
protecting liver against CCl4-induced injury in rats.
Results
Preparation of rhKGF-1
The cDNA of rhKGF-1 was cloned into the NdeI and BamHI
restriction sites of pET-GST and then the recombinant vector was
used to transform bacterial host BL21(DE3). The transformants
bearing the expression vector were induced with IPTG and then
lyzed, and the soluble fraction was collected following centrifuga-
tion and filtration. SDS-PAGE analysis of the lysate supernatant
showed that the recombinant protein was expressed as a soluble
product with an apparent molecular weight of about 38 kDa
corresponding to the predicted protein product of GST-KGF-1
(Figure 1A). The soluble product was then purified as described
in Materials and Methods. Next, the N-terminal GST tag was cleaved
from GST-rhKGF-1 by digestion with thrombin according to the
manufacturer’s instruction. Residual GST that survived enzymatic
treatment together with the remaining uncleaved GST-rhKGF-1
were then removed from rhKGF-1 preparation by a two step
chromatography using CM Sepharose Fast Flow and heparin–
Sepharose columns. As demonstrated in Figure 1B and 1C,
SDS-PAGE and scanning densitometry analysis showed that the
recovered untagged rhKGF-1 was homogenous and its purity is
over 95%.
Preparation of Solid-Phase Mono-PEGylated rhKGF-1
Given the fact that rhKGF-1 has a high affinity for heparin, the
recombinant protein was first adsorbed to a heparin affinity
column. Next, mPEG20 kDa-butyraldehyde (Alk-mPEG) was
introduced to a reducing agent and then the mixture was
circulated through the heparin column at very low flow rate.
Upon circulation of Alk-mPEG through the column, Alk-mPEG
covalently attached to N-terminal residue (a-amine) of rhKGF-1
via a reductive alkylation. To determine the optimal conditions for
the site-specific PEGylation of the recombinant protein, the effects
of different PEG/protein molar ratios (ranging from 5/1 to 30/1)
and reaction times (ranging from 2 to 12 hours) on the yield and
efficiency of PEGylation were examined. Our data showed that
the optimized yield of mono-PEGylation was achieved when the
reaction was performed at pH 6 for 8 hours using a PEG/protein
molar ratio of 10/1 (Figure 2A). In fact, our SDS-PAGE and
scanning densitometry analysis showed that when the optimal
Figure 1. SDS-PAGE analysis of expression and purification of rhKGF-1. Panel A. SDS-PAGE analysis of the fractions collected from
Glutathione Sepharose chromatography. Lane M, molecular weight standards; lane 1, the cell lysate supernatant of BL21 (DE3) containing pET- GST-
KGF-1 induced with 1.0 mM IPTG for 4 h; lane 2, the flow-through fraction; lane 3, the fraction eluted with 50 mM Tris-HCl, 10 mM reduced
glutathione, pH 8.0. Panel B. SDS-PAGE analysis of the fractions collected from CM Sepharose chromatography. Lane M, molecular weight standards;
lane 4, the GST-rhKGF-1 fusion protein after treatment with thrombin; lane 5, the flow-through fraction; lane 6, NaCl-eluted fraction. Panel C. SDS-
PAGE analysis of Heparin Sepharose chromatography. Lane M, molecular weight standards; lane 7, NaCl-eluted fraction from CM Sepharose Fast Flow
column; lane 8, 0.45 M NaCl-eluted fraction; lane 8, 0.6 M NaCl-eluted fraction.
doi:10.1371/journal.pone.0036423.g001
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used in the reaction was successfully mono-PEGylated.
To separate PEGylated rhKGF-1 from non-PEGylated rhKGF-
1, the bound materials, i.e. both PEGylated and non-PEGylated
rhKGF-1, on the heparin column was eluted using a high salt
sodium phosphate buffer and then the eluted protein sample was
applied on a Sepharose G25 column to be desalted. The desalted
protein sample was then subjected to a salt gradient cation-
exchange chromatography on a HiTrap SP Sepharose Fast Flow
column. After the cation-exchange chromatography, PEGylated
and non-PEGylated rhKGF-1 were eluted in two separate peaks as
confirmed by SDS-PAGE analysis (Figure 2B), suggesting that
the modification alters the electrostatic properties of rhKGF-1
surface.
Validation of Solid-Phase PEGylated rhKGF-1
To confirm that rhKGF-1 was mono-PEGylated, MALDI-TOF
mass spectrometry (MALDI-TOF-MS) was employed. Our MS
data showed that the PEGylated rhKGF-1 had a molecular weight
of 36997.50 Da (Figure 3A), therefore confirmed that a single
20 kD PEG molecule was conjugated to rhKGF-1 (16297.57 Da)
(Figure 3B). The broad MS peak corresponding to PEGylated
rhKGF-1 was most likely due to the PEG polydispersity as
reported before [20]. Next, an automated N-terminal sequencing
by Edman degradation was employed to validate the site of
PEGylation on rhKGF-1. Using this method of sequencing, the
five N-terminal amino acids (Ser-Tyr-Asp-Tyr-Met) were detected
only in the non-PEGlyated rhKGF-1 (Figure 3C) but not in the
PEGylated rhKGF-1 (Figure 3D). The N-terminal residues of
PEGylated rhKGF-1 were not detected because the covalent
attachment of PEG to the N-terminal a-amino group did not allow
the N-terminal Ser residue to be modified by 1-fluoro-2,4-
dinitrobenzene(FDNB) through the sequencing reaction therefore
made it unrecoverable [21]. Taken together, these sequencing
data unambiguously corroborated site-specific N-terminal PEGy-
lation of rhKGF-1.
Analysis of Bioactivity of Solid-Phase PEGylated rhKGF-1
To evaluate the bioacitivity of PEGylated rhKGF-1, prolifer-
ative effect of PEGylated rhKGF-1 on NIH 3T3 cells was
compared to that of non-PEGylated rhKGF-1 using standard
MTT assay. As shown in Table 1, non-PEGylated rhKGF-1 and
PEGylated rhKGF-1 induced comparable mitogenic response in
NIH 3T3 cells, demonstrating that the mono-PEGylation had no
adverse effect on proliferative activity of rhKGF-1. Furthermore,
we qualitatively analyzed the effect of rhKGF-1 PEGylation on the
KGF-1-induced activation of MAP kinase pathway, a key KGF-1
signaling pathway that is involved in cell proliferation, in NIH 3T3
cells. As shown in Figure 4, similar to rhKGF-1, PEGylated
rhKGF-1 triggered intense phosphorylation of Erk1 and Erk2,
further confirming that the solid-phase PEGylation did not impact
on the bioactivity of rhKGF-1.
Effect of Solid-Phase PEGylation on the Structural
Integrity and Stability of rhKGF-1
To investigate whether the solid-phase PEGlyation affects the
rhKGF-1 structure, the secondary structure of PEGylated rhKGF-
1 was compared to that of non-PEGylated rhKGF-1 using circular
dichroism (CD) spectroscopy. Far-UV CD spectra recorded for
PEGylated rhKGF-1 was comparable to that of non-PEGylated
rhKGF-1 (Figure 5A), demonstrating that the solid-phase
PEGylation of rhKGF-1 did not alter the secondary structure of
rhKGF-1.
Therapeutic proteins are exposed to a variety of stresses that can
result in protein unfolding or degradation. Using a rational
stabilization method, the biopharmaceutical proteins can be
modified such that their structures and activities are substantially
more robust with respect to protease exposures, changes in
temperature and pH [19,22]. PEGylation, as a simple strategy for
protein stabilization, would be expected to increase proteolytic
resistance of rhKGF-1. To test this, the stability of rhKGF-1 and
its mono-PEGylated derivative in the presence of trypsin were
investigated in vitro. We selected trypsin because this proteolytic
enzyme has been extensively used to investigate resistance of a
protein to enzymatic digestion [23,24]. As shown in Figure 5B,
there was significant difference in the amount of degradation
between non-PEGylated and PEGylated rhKGF-1 incubated with
trypsin for various time periods. After incubation with trypsin for
60 min at 37uC, nearly 58.2% of PEGylated rhKGF-1 still
remained intact, whereas only about 27.4% non-PEGylated
rhKGF-1 was left intact, indicating that solid-phase PEGylation
significantly increased resistance of rhKGF-1 to proteolysis.
Protein aggregation is another major stability problem of
therapeutic proteins. To check whether PEGylation can improve
Figure 2. SDS-PAGE analysis and elution profile of solid-phase PEGylation reaction mixture. Panel A. SDS-PAGE analysis of solid-phase
PEGylated rhKGF-1. Lane M, molecular weight standards; lane a, solid-phase PEGylation products obtained at PEG-to-protein ratio of 10/1 and
reaction time of 8 h; lane b, non-PEGylated rhKGF-1. Panel B. Elution profile of PEGylation reaction mixture on a SP Sepharose Fast Flow column. The
Insert panel shows SDS-PAGE analysis of the fractions collected from SP Sepharose chromatography.
doi:10.1371/journal.pone.0036423.g002
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rhKGF-1 was compared to that of rhKGF-1 by measuring the
amount of the protein aggregates accumulated at elevated
temperatures over a long period of time. As shown in
Figure 5C, the PEGylation showed pronounced stabilizing effect
on rhKGF-1 by preventing aggregation. At 37uC, the rhKGF-1
sample had already lost about 76% of the soluble rhKGF-1 over
three days, while the PEGylated sample showed almost no loss. At
45uC, the rhKGF-1 sample almost rapidly lost all the remaining
soluble rhKGF-1, whereas the PEGylated sample showed much
slower loss rate of the soluble PEGylated rhKGF-1. This
comparative analysis, therefore, demonstrated that PEGylation
significantly suppressed tendency of rhKGF-1 for aggregation.
It is known that rhKGF-1 rapidly inactivated at acidic
conditions [22]. To test whether PEGylation can protect
rhKGF-1 against low pH-induced inactivation, using a mitogenic
bioassay, the bioactivity of PEGylated rhKGF-1 was compared to
that of rhKGF-1 within a pH range between 1.5 to 7 (Figure 5D).
The bioactivities were normalized to their values at neutral pH
(pH 7.0). The mitogenic bioassay data demonstrated that the
in vitro bioactivity of both rhKGF-1 and its PEGylated derivative
declined as pH decreased. However, compared to rhKGF-1 that
lost 63% of its bioactivity at pH 5.0, PEGylated rhKGF-1 showed
about 25% loss in its bioactivity. When the pH value decreased to
4.0, rhKGF-1 almost lost all of its bioactivity, whereas solid-phase
PEGylated rhKGF-1 still retained 28% of its bioacitivity. These
bioassay analyses, therefore, confirmed that PEGylation could
improve biostability of rhKGF-1 in acidic pH.
Pharmacokinetic Study of Solid-Phase PEGylated rhKGF-1
in Rats
The in vivo half-life times of the two forms of rhKGF-1 were
analyzed by intravenously (i.v.) injecting a single dose of
100 mg/kg of intact or PEGylated rhKGF-1 in male SD rats
and measurements of the dynamic levels of two proteins in the
blood using the KGF (FGF-7)-basic Mini ELISA Development
Kit. Based on the pharmacokinetic curves shown in Figure 6A,
the plasma elimination half-life (t1/2) was calculated with Drug and
Statistics Software (DAS, Version. 2.0; Mathematical Pharmacol-
ogy Professional Committee of China) and the equation described
Figure 3. Validation of the solid-phase PEGylated rhKGF-1. Panel A, MALDI-TOF mass spectrometry of PEGylated rhKGF-1 showing the
molecular mass of PEGylated rhKGF-1 (36997 Da). Panel B, MALDI-TOF mass spectrometry of non-PEGylated rhKGF-1 showing the molecular mass of
non-PEGylated rhKGF-1 (16297 Da). Panel C, D. N-terminal sequencing of non-PEGylated and PEGylated rhKGF-1 by Edman degradation method.
doi:10.1371/journal.pone.0036423.g003
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reports [25,26], our pharmacokinetic data showed that the non-
PEGylated rhKGF-1 was eliminated with a plasma half-life (t1/2)
of about 3.22 h. Importantly, PEGylation increased the plasma
half-life of rhKGF-1 to about 27.26 h, an 8.2-fold increase
compared to intact rhKGF-1 (Figure 6B).
Comparison of Hepatoprotective Effects of Solid-Phase
PEGylated rhKGF-1 and Intact rhKGF-1 Using a Rat Model
of Acute Liver Failure
Our biochemical analyses clearly demonstrated that PEGylated
rhKGF-1 has a similar in vitro bioactivity, but significantly higher in
vitro and in vivo biostability compared to its intact counterpart. We
next compared the therapeutic effect of PEGylated rhKGF-1 to
that of intact rhKGF-1 using a rat model of acute hepatic failure.
To this end, two groups of rats (n=12) were pre-treated with a
single dose (0.1 mmol/kg) of either rhKGF-1 or PEGylated
rhKGF-1, and 24 hours later they were intoxicated once by
CCl4 (2.5 mL/kg). The hepatoprotective effects of rhKGF-1 and
PEGylated rhKGF-1 were then studied by comparing the serum
levels of aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) just before the rhKGF-1/PEGylated rhKGF-1
injection and 4 hours after the CCl4 administration. As a control
group, 12 rats were only treated with normal saline. Additionally,
an injury- model group (n=12) was pretreated with normal saline
prior to intoxication by CCl4. As shown in Figure 7, compared to
the healthy control group in which the serum levels of AST and
ALT remained unchanged during the course of experiments, the
serum levels of the aminotransferases (AST and ALT) in the
injury-model group were significantly increased (2-fold and 4.5-
fold, respectively) above the baseline levels after CCl4 administra-
tion. As expected, that the pretreatment of the test groups with
either intact rhKGF-1 or PEGylated rhKGF-1 considerably
protected liver against injury in the CCl4-intoxicated animals
(Figure 7). Importantly, PEGylated rhKGF-1 afforded a better
hepatoprotection compared to intact rhKGF-1. This is evidenced
by the fact that following CCl4 intoxication, the serum level of
AST and ALT were elevated 1.5-fold and 2.5-fold, respectively,
above baseline levels in the rats pretreated with rhKGF-1, whereas
the enzyme levels were raised 1.1-fold and 1.5-fold, respectively,
above baselines in the serum of animals pretreated with PEGylated
rhKGF-1 (Figure 7).
Discussion
A wealth of pharmacological studies has been previously shown
that KGF-1, a member of the FGF family, has a high therapeutic
potential in preventing oral mucositis in patients with haemato-
logical malignancies [8,26]. In addition, several in vivo studies using
different animal models have shown that recombinant human
KGF-1 could enhance the regenerative capacity of epithelial
tissues and protect them from a variety of toxic exposures [6,7].
However, similar to other therapeutic proteins, the inherent
sensitivities associated with rhKGF-1, including thermal instabil-
ity, degradation by proteolysis, and short half-life in vivo, have
restricted its clinical applications [10,22]. A widely used method to
evade these limitations is the covalent attachment of PEG
molecular to a protein using a solution-phase batch process, a
technique is known as solution-phase PEGylation. This approach
employs compounds that couple PEG to free amines, typically at
lysine residues or at the N-terminal amino acid [27,28]. A critical
limitation of this method is that proteins typically contain several
lysine residues, in addition to the N-terminal amino acid. The
PEG moiety can couple to the protein at any of the available free
amines, leading to a heterogeneous product mixture consisting of
mono-, di-, tri-, etc, PEGylated species [19,28]. The different
PEGylated species often have different intrinsic biological activities
[29,30]. This can restrict development of any therapeutic protein
including rhKGF-1 because predictability of biological activity
and manufacturing reproducibility are essential for regulatory
approval. In addition, multiple steps of purification are required to
Figure 4. The effect of rhKGF-1 PEGylation on MAP kinase
activation. Panel A. NIH 3T3 fibroblasts were stimulated with rhKGF-1
or PEGylated rhKGF-1 at three does 1.5 mM, 3 mM, and 6 mM, and
phosphorylation courses of ERK1/2 (p-ERK) were measured by
immunoblotting alongside total ERK as loading controls. The blots
shown are representative of three independent experiments; Panel B.
Semi-quantitative analysis of the protein bands in Panel A. *, p,0.05 vs
Normal control;
#,p ,0.05 vs the corresponding non-PEGylated rhKGF-1
group.
doi:10.1371/journal.pone.0036423.g004
Table 1. Biological activity of native rhKGF-1 and PEGylated
rhKGF-1.
rhKGF-1
Alk-PEGylated
rhKGF-1 by
solid-phase
Mal-PEGylated
rhKGF-1 by
solution-phase
Mean biological
Activity (IU/mmol)
2.21610
5 1.98610
5 3.82610
4
Relative activity (%) 100% 89.6% 17.3%
doi:10.1371/journal.pone.0036423.t001
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unreacted PEG, and multi-PEGylated species.
It has been previously shown that site-specific PEGylation can
overcome the problems of product heterogeneity caused by the
solution-phase amine-PEGylation [13,14]. Site-specific PEGyla-
tion can be achieved by the covalent attachment of cysteine-
reactive PEG molecule (mPEG-maleimide, Mal-mPEG) to the
thiol group of a ‘‘free’’ cysteine residue, i.e., a cysteine residue not
involved in a disulfide bond, in a protein structure [28,31]. The
primary structure of rhKGF-1 produced in our laboratory
contains five cysteine residues located at positions 1, 15, 40, 102
and 106. Previous studies have shown two disulfide-bonds between
Figure 5. The effect of solid-phase PEGylation on the structural integrity and stability of rhKGF-1. Panel A. Far-UV CD spectra of non-
PEGylated (black line) and solid-phase PEGylated rhKGF-1 (red line). The ellipticities are reported as mean residue ellipticity (MRE) (deg cm
2 dmol
21).
Panel B. Effect of PEGyaltion on the proteolytic stability of rhKGF-1. PEGylated and intact rhKGF-1 were incubated with trypsin with a molar ratio of
10/1 (protein/trypsin) at 37uC for the indicated periods of times. Trypsin-treated rhKGF-1 was examined for the protein integrity by SDS-PAGE. The
bands representing PEGylated and intact rhKGF-1 were quantified by densitometry scanning. The band densities of non-trypsin-treated intact and
PEGylated rhKGF-1 are considered as 100% (indicated as control), while the band densities of trypsin-treated PEGylated or intact rhKGF-1 are
presented as relative percentage to the control. *, p,0.05 vs the corresponding intact rhKGF-1 group. Panel C. Kinetic plots of remaining soluble non-
PEGylated rhKGF-1 (black square) and PEGylated rhKGF-1 (red circle). The soluble protein concentration was determined by Bicinchoninic acid (BCA)
kit. Samples were first incubated at 37uC for 3 days and then transferred to 45uC for the rest of the experiments. Pane D. Effect of pH on in vitro
bioactivity of non-PEGylated rhKGF-1 (black square) and PEGylated rhKGF-1 (red circle).
doi:10.1371/journal.pone.0036423.g005
Figure 6. Pharmacokinetics study of solid-phase PEGylated rhKGF-1 in rats. Panel A. Normal male SD rats were injected intravenously with
100 mg/kg rhKGF-1 (open circle), and PEGylated rhKGF-1 (solid circle). Blood samples were collected at the indicated time points. The amount of
rhKGF-1 was measured by Human KGF-basic Mini ELISA Development Kit. A standard curve was made for each rhKGF-1, n=6. Values are the
mean6SD. Panel B. Comparison of half-life of non-PEGylated rhKGF-1 and PEGylated rhKGF-1. *, p,0.01 vs the corresponding non-PEGylated rhKGF-1
group.
doi:10.1371/journal.pone.0036423.g006
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rhKGF-1 [22], thus suggesting that the thiol group of Cys 40 is
free available for site-specific PEGylation. Since we failed in our
attempts to couple this free cysteine (Cys 40) with Mal-mPEG, we
decided to conjugate Mal-mPEG with rhKGF-1 at Cys 40 in the
presence of chaotrope, i.e. urea. Urea, as a chaotrope, can disrupt
the protein–protein and protein–water contacts and interacts
preferentially with the protein molecule [32], perhaps exposing
Cys 40 to the solvent environment. Although the site-specific
PEGylation in the presence of 2 M urea was successful (Figure
S1A), this modification had detrimental effects on the bioactivity
(Table 1) and structure (Figure S1B) of rhKGF-1. This is most
likely because Cys 40 is buried in the hydrophobic core of rhKGF-
1( Figure S1C) [22] and plays an important role in maintaining
the structural integrity of the protein.
Having failed to produce a bioactive cysteine-PEGylated
rhKGF-1, we decided to selectively PEGylated the N-terminal
residue of the protein by a reductive alkylation at low pH in
solution phase. Under such reaction conditions, PEGylation at the
N-terminal amino group (pKa 7.6 to 8.0) is favored over the e-
amino groups of lysine residues (pKa 10.0 to 10.2). This approach
has been previously utilized to PEGylate epidermal growth factor
(EGF) [30], recombinant human endostatin [33], interferon b-1b
[34] and rhFGF21 [20]. N-terminal site-specific PEGylated
proteins are generally synthesized by solution-phase chemical
reactions where reactants, product, and byproduct remain within
the same homogeneous reaction mixture until separation.
Therefore, even when reductive alkylation at low pH is carried
out, synthesis of some undesirable PEGylated forms is inevitable.
As shown in Figure S2, under optimal conditions of PEG-to-
protein molar ratio (5:1), reaction time (8 hours) and pH (pH 6),
the reductive alkylation (PEGylation) of amino groups in rhKGF-1
yielded both the mono-PEGylated (46.1% of the total protein) and
di-PEGylated (11.4% of the total protein) forms of the protein.
Given separation of the mono- and di-PEGylated species of
rhKGF-1 was practically unfeasible by typical heparin affinity, size
exclusion and ion exchange chromatography methods (data not
shown), we used a novel solid-phase PEGylation approach to
generate homogenously N-terminal mono-PEGylated rhKGF-1.
In this approach, we immobilized rhKGF-1 on a heparin-
sepharose column and then passed activated Alk-mPEG through
the column. As confirmed by our densitometry, mass spectrometry
and sequencing analyses, under optimal conditions, over 40% of
rhKGF-1 utilized in the PEGylation reaction is homogenously
mono-PEGylated at its N-terminal residue. We have previously
shown that the solution-phase PEGylation alters heparin-binding
ability of rhKGF-2 [35]. Our salt gradient heparin-sepharose
affinity chromatography has shown that the modified rhKGF-2 is
eluted at lower salt concentration compared to the intact rhKGF-
2, indicating that the solution-phase PEGylation reduces the
heparin-binding affinity of rhKGF-2 [35]. The solid-phase
PEGylation method reported here, on the contrary, enables us
to orientate the protein so that its heparin- and most likely
receptor-binding sites are held towards the solid-phase interface,
thus allowing us to restrict conjugations at the sites that interfere
with the activity of rhKGF-1. This is confirmed by our heparin-
sepharose affinity chromatography data demonstrating that
PEGylated rhKGF-1 and intact rhKGF-1 bind with a similar
affinity to the heparin-sepharose column and co-elute from the
column using a linear salt gradient (Figure S3). Furthermore, our
bioactivity data show that, similar to rhKGF-1, solid-phase
PEGylated rhKGF-1 is able to induce proliferatation through
the activation of MAPK/Erk pathway in NIH 3T3 cells, thus
suggesting that solid-phase PEGylation does not adversely affect
the heparin- and receptor-binding ability of rhKGF-1. This
conclusion is also supported by our CD analysis showing that
solid-phase PEGylated rhKGF-1 and rhKGF-1 have similar
secondary structures (Figure 5A).
PEGylation may affect physicochemical and/or pharmacoki-
netic features of the proteins by steric hindrance and conforma-
tional changes [19,20]. Here we demonstrate that the solid-phase
PEGylation increases the resistance of rhKGF-1 to trypsin
treatment (Figure 5B), and to changes in temperature and pH
(Figure 5C and D), compared to non-PEGylated rhKGF-1. The
increased resistance to proteolytic degradation presumably reflects
the steric hindrance of the PEG strands that act as direct barriers
to cleavage. The aggregation observed at the elevated tempera-
tures (37uC, and 45uC) may be explained by reduced thermody-
namic stability of the protein structure and an increased
hydrophobic interaction from exposed hydrophobic patches.
The conjugated PEG might swim around the hydrophobic
patches of rhKGF-1 to suppress hydrophobic interactions. This
Figure 7. Effect of solid-phase PEGylated rhKGF-1 on serum AST and ALT levels in rats intoxicated with CCl4. 48 male SD rats were
randomly divided into four groups (12 rats/group): enalpril interventional group A (rhKGF-1-pretreated groups), enalpril interventional group B
(PEGylated rhKGF-1-pretreated groups), injury-model group and healthy control group. The test groups were pretreated with non-PEGylated and
PEGylated rhKGF-1 24 hours prior to 2.5 mL/kg CCl4 administration. Four hours after the intraperitoneal injection of CCl4, rats were killed and their
serum AST/ALT levels were determined. *, p,0.05 vs control group;
#,p ,0.05 vs injury-model group;
ss,p ,0.05 between indicated groups.
doi:10.1371/journal.pone.0036423.g007
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interactions that suppress the aggregation during the process of
in vitro refolding [36]. Taken together, our stability analyses
suggest that Alk-mPEG modifies rhKGF-1 such that its structure
and activity are substantially more robust with respect to stresses
that can cause protein unfolding or degradation.
From our pharmacokinetic data, it appears that the solid-phase
PEGylation improves the plasma half-life of rhKGF-1 to about
28 hours, which is over eight-times longer than that of intact
rhKGF-1 (Figure 6). Mono-PEGylation increases the circulating
half-life of rhKGF-1 most likely by reducing proteolysis, and
restricting tissue-distribution such as glomerular filtration by the
kidney and hepatic uptake. This effect is attributed to the
increased molecular size and steric hindrance that result from
attaching PEG to the protein [37].
Another important finding of the present study is physiological
confirmation that the solid-phase PEGylated rhKGF-1 is more
effective than intact rhKGF-1 in protecting liver against CCl4-
induced injury in rats. This is evidenced by the fact that serum
levels of the liver injury biomarkers, ALT and AST, in the CCl4-
intoxicated rats pretreated with rhKGF-1 were significantly higher
than in the animals pretreated with PEGylated rhKGF-1
(Figure 7). FGFs, including KGF-1 regulate liver development
[38,39], and regeneration [40,41], therefore potentially provide a
line of defense against CCl4-induced hepatocellular necrosis.
Moreover, Bohm et al., [42] have previously shown that KGF-1
activates hepatocyte FGFR2-IIIb, reducing CCl4-induced centri-
lobular necrosis and inflammation. These authors have suggested
that KGF-1 highly up-regulates expressions of two transcriptional
regulators, Dbp and Tef, thereby increasing expression of
detoxifying cytochrome P450 enzymes in mouse hepatocytes.
This increase in expression of genes that control detoxification,
could additionally provide a potential mechanism by which KGF
detoxifies CCl4 and protects rats from CCl4-induced hepatic
damage. The increased in vivo biostability of PEGylated rhKGF-1
relative to intact rhKGF-1 may explain the observed higher
hepatoprotection.
In summary, in order to increase rhKGF-1’s stability, half-life
and therapeutic potency, we N-terminally mono-PEGylated
rhKGF-1 for the first time using a novel ‘‘on column’’ (Heparin-
sepharose column) PEGylation method. The PEGylated rhKGF-1
was purified to homogeneity using a cation-exchange chromatog-
raphy. Similar to the intact rhKGF-1, PEGylated rhKGF-1
induced proliferation via the activation of MAPK/Erk pathway in
NIH 3T3 cells. The solid-phase PEGylation remarkably increased
the in vivo and in vitro stability without altering the over all structure
and compromising the heparin- and receptor-binding ability of
rhKGF-1. The solid-phase PEGylation also considerably im-
proved plasma half-life of rhKGF-1 in vivo. Importantly,
PEGylated rhKGF-1 afforded a greater hepatoprotection against
CCl4-induced liver damage in rats compared to rhKGF-1.
Collectively, using the sold-phase PEGylation approach reported
here, we developed a rhKGF-1 with enhanced stability and an
extended plasma half-life for therapeutic applications.
Materials and Methods
Reagents
PyrobestH DNA Polymerase and restriction enzymes NdeI and
XhoI were purchased from TaKaRa Company (Japan). PCR
purification kit, gel extraction kit, and plasmid miniprep kit were
obtained from the Promega Company (USA). mPEG20 kDa-
butyraldehyde (Alk-mPEG) and mPEG20 kDa-maleimide (Mal-
mPEG) were purchased from Sigma–Aldrich (St. Louis, MO,
USA). Heparin-Sepharose column, Sepharose G25 column and
AKTA purifier were purchased from GE healthcare (Piscataway,
NJ, USA). Enhanced chemiluminescence (ECL) detection kit was
from Pierce (Rockford, IL, USA). Anti-Erk1/Erk2 rabbit mAb,
anti-phospho-Erk1/Erk2 (Thr202/Tyr204) rabbit mAb were
purchased from Cell Signaling Technology (Danvers, MA,
USA). KGF(FGF-7)-basic Mini ELISA Development Kit was
purchased from PeproTech (Princeton, NJ, USA). The protein
assay reagent used for quantitative protein analysis was purchased
from Bio-Rad (Hercules, CA, USA). Other reagents, unless
otherwise indicated, were of the highest quality commercially
available.
Expression and Purification of rhKGF-1
RhKGF-1 was expressed as a fusion protein with bacterial
glutathione-S-transferase (GST) at the N-terminus as described
previously [43]. Briefly, the recombinant plasmid, pET-GST-
KGF-1 was transformed into Escherichia coli BL21 (DE3) cells, then
BL21 (DE3) cells were incubated at 37uC in Luria-Bertani (LB)
medium containing ampicillin (50 mg/mL) until cell density
reached an OD600 of 0.6. The cells were then transferred to
30uC, and 0.4 M isopropyl-1-thio-b-d-galactopyranoside (IPTG,
Gold BioTechnology, St. Louis, MO) was added to the medium to
induce expression of the recombinant product. After incubation
for 3–4 h, the bacteria were collected by centrifugation and the
cell pellet was then resuspended in 25 mM Tris-HCl (pH 7.2),
1 mM EDTA, 0.6–0.9 M NaCl, and 1 mM phenylmethylsulfonyl
fluoride (PMSF), and then the cells were lysed by sonication and
clarified by centrifugation. Soluble recombinant product was
recovered from bacterial lysates by Glutathione Sepharose
chromatography. Then, the GST and a portion of the N-terminal
sequence was removed by incubation of the immobilized fusion
product with 5 mg/mL thrombin in phosphate buffer (PB, pH 7.0)
for 24 h at room temperature. The incubation mixture was
applied to a CM Sepharose Fast Flow column (1 mL bed volume)
pre-equilibrated with 15 column volumes (CVs) of binding buffer
(20 mM sodium phosphate buffer, SPB, pH 7.0) at a rate of
0.5 mL/min. The sample was washed with 10 CVs of binding
buffer, and then eluted with elution buffer A (0.3 M NaCl, 20 mM
SPB, pH 7.0) , and B (1.0 M NaCl, 20 mM SPB, pH 7.0) over 10
CVs. The final product was further purified using Heparin
Sepharose column with a PB elution buffer (pH 7.0) containing
0.6 M NaCl. All elution fractions were collected and analyzed by
12% SDS-PAGE, and then the rhKGF-1 fractions were stored at
280uC for the subsequent experiments.
Solution-Phase PEGylation of rhKGF-1
PEGylation of rhKGF-1 with Alk-mPEG was performed at
room temperature in a sodium phosphate buffer (20 mM, pH 6.0)
in the presence of 20 mM NaBH3CN. Alk-mPEG was allowed to
react with the protein at various PEG-to-protein molar ratios (5,
10, 15, and 20) for different periods of time. To determine the
optimal conditions for the Mal-mPEG modification of rhKGF-1,
the PEGylation was performed at room temperature in 20 mM
sodium phosphate buffer at different PEG-to-protein ratios, pH,
and reaction times. All reactions were terminated by adding 2%
(w/v) glycine and then analyzed by 12% SDS -PAGE.
Solid-Phase PEGylation of rhKGF-1
Three major procedures were performed for the solid-phase
PEGylation of rhKGF-1: 1) Two mL of 0.1 mM rhKGF-1 in
20 mM sodium phosphate buffer (pH 6.0) was applied and bound
on Heparin-Sepharose column. Due to the high binding affinity,
rhKGF-1 completely bound on the column as evidenced by the
Solid-Phase Site-Specific PEGylation of rhKGF-1
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application of the protein sample on the column. 2) A solution
containing 4.8 mL of 0.5 mM Alk-mPEG and 20 mM NaBH3CN
was circulated through the column at low flow rate
(0.01,0.03 mL/min) for different periods of time (2, 4, 8 or
12 h). At the end, 30 mL of equilibrium buffer (20 mM sodium
phosphate buffer, pH 6.0) was used to wash unreacted Alk-mPEG.
3) The reaction complex was completely eluted by applying 2 M
NaCl in sodium phosphate buffer at a flow rate of 1 mL/min. The
eluted fraction was collected and desalted by Sepharose G25
column and stored at 220uC. PEGylation yield was estimated by
12% SDS-PAGE and densitometry quantification as previously
reported [19,44].
Purification of Solid-Phase PEGylated rhKGF-1
The reaction mixture obtained from the Sepharose G25
chromatography was applied on a SP Sepharose Fast Flow
column (1 mL bed volume) pre-equilibrated with 15 column
volumes (CVs) of binding buffer (20 mM sodium phosphate buffer,
SPB, pH 7.0) at a flow rate of 0.5 mL/min. The sample was
washed with 10 CVs of binding buffer, and then eluted with a salt
gradient (from buffer A (0 M NaCl, 20 mM SPB, pH 7.0) to
buffer B (1.0 M NaCl, 20 mM SPB, pH 7.0)). All elution fractions
were collected and analyzed by 12% SDS-PAGE.
Mass Spectrometry and N-Terminal Analysis of PEGylated
rhKGF-1
Mass spectra were acquired using an Applied Biosystems
Voyager System DE PRO MALDI-TOF mass spectrometer with
a nitrogen laser. The matrix was a saturated solution of R-
cyano-4-hydroxycinnamic acid in a 50/50 mixture of acetonitrile
and water containing 0.1% trifluoroacetic acid. The mono-
PEGylated protein and matrix were mixed at a ratio of 1/1,
and then 1 mL sample was spotted onto a 100-well sample plate.
All spectra were recorded on a Bruker Ultraflex instrument
(Bruker Daltonik, Germany) and acquired in positive mode over
the range 600–2500 Da under reflection conditions (20 kV
accelerating voltage, 350 ns extraction delay time) and 2–
100 kDa under linear conditions (25 kV accelerating voltage,
750 ns extraction delay time). The N-terminal amino acid
sequence of PEGylated rhKGF-1 was examined by Edman
degradation method [45], and followed by MALDI-TOF mass
spectroscopy as described above.
Analysis of the Mitogenic Activity of PEGylated rhKGF-1
We used NIH 3T3 cell line (American Type Culture Collection,
Rockville, MD) to determine the proliferative effect of PEGylated
rhKGF-1. First, the cells were seeded in 96-well plates with 5610
3
cells per well and incubated for 24 h. Then they were washed with
phosphate buffered saline (PBS) and starved-cultured in the
corresponding low glucose Dulbecco’s Modified Eagle’s Medium
(DMEM) containing 0.4% Fetal Bovine Serum (FBS) for 24 h.
The cells were then treated with 3 mM native rhKGF-1, 3 mM
PEGylated rhKGF-1 for 24 h, and finally the number of viable
cells was detected by the methylthiazoletetrazolium (MTT)
method as previously reported [46,47].
Western Blot Analysis for the MAP Kinase Activation of
PEGylated rhKGF-1
NIH 3T3 cells were treated with rhKGF-1 or PEGylated
rhKGF-1 at three doses 1.5 mM, 3 mM, and 6 mM. After washing
with PBS for three times, the cells were homogenized in a lysis
buffer. Total cellular proteins were collected by centrifuging at
12,000 rpm at 4uC. The protein concentration was then
determined by Bicinchoninic acid (BCA) kit. Next, the protein
samples were mixed with loading buffer and subjected to
electrophoresis on a 12% SDS-PAGE gel at 110 V for 100 min.
Following transferring the proteins to a Polyvinylidine Fluoride
(PVDF) membrane (Millipore-Billerica, MA, USA), the membrane
was blocked with 5% nonfat milk for 2 hours at room
temperature. The membrane was then washed three times with
Tris-Buffered Saline containing 0.1% Tween-20 (TBST) and
incubated with primary antibody at 4uC overnight. The
membrane was then washed three times with TBST, and
secondary HRP-conjugated antibody was applied and the
membrane was incubated for 1 h at room temperature. Finally,
immunoreactive protein bands were visualized by ECL system,
and quantified by optical densitometer.
Circular Dichroism Spectroscopy Analysis
The secondary structures of rhKGF-1 and PEGylated rhKGF-1
were determined with a circular dichroism (CD) spectropolarim-
eter (Model J-810, Jasco, Japan). Far-UV CD spectra were
recorded at wavelengths between 190 and 250 nm using a
0.1 cm path length cell at 25uC with a protein concentration of
6 mM in 10 mM PBS, pH 7.0. Each spectrum was a representa-
tive of three scans. The CD spectra were corrected for buffer
contributions.
Effect of Solid-Phase PEGylation on the In Vitro Stability
of rhKGF-1
Trypsin from Promega, Inc. (Madison, WI, U.S.A.) was
dissolved at 100 mg/mL in 50 mM ammonium bicarbonate
buffer (pH 7.8). PEGylated and non-PEGylated rhKGF-1 were
treated with trypsin at a molar ratio of 10/1 (protein/trypsin) and
37uC for different periods of time as indicated and then 50 mLo f
20% TFA was added to stop the digestion reaction. The samples
were then subjected to SDS-PAGE to examine the protein
integrity.
Samples for storage stabilities tests contained 1.0 mg/mL non-
PEGylated and PEGylated rhKGF-1 prepared in 20 mM SPB
(pH 7.0). These samples (1 mL each) were aliquoted into 3 mL
type 1 glass vials in a sterile laminar flow hood. The vials were
sealed with rubber stoppers (1888 Teflon, West Co.) and 13 mm
flip-off aluminum seals were crimped in place. The vials were
placed in the incubators set at 37uC for 3 days, then some of the
samples were transferred to another incubators set at 45uC. After
incubation for different periods of time as indicated, 100 mL of the
samples were withdrawn and centrifuged at 4200 rpm. The
supernatant of each sample was collected and finally the soluble
protein concentration was determined using Bicinchoninic acid
(BCA) kit.
To determine the pH stability of PEGylated and non-
PEGylated rhKGF-1, the protein samples prepared in different
buffers with various pH (4–5, 25 mM acetate; pH 6–7, 25 mM
Hepes) were incubated for 30 min at room temperature. Following
incubation, the protein samples were diluted 5000 times by
bioassay medium and than used for mitogenic bioassay. The in vitro
bioactivities of proteins were then measured by mitogenic bioassay
as described above.
Animals and Surgical Procedures
Normal male SD rats (220–250 g) were used based on the
procedures approved by the Animals Care and Use Committee
from Jilin University [license No. SYXK(Ji)2010-0007]. The
animal production license is No. SCXK 2010-0003.
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rhKGF-1 in Rats
Following intravenous (i.v.) injection of the intact and
PEGylated proteins at a dose of 100 mg/kg body weight (six
animals in each group), blood samples were obtained at time
points indicated. Serum levels of the test proteins were quantified
using KGF(FGF-7)-basic Mini ELISA Development Kit (Pepro-
Tech, USA; sensitivity range of 63 to 4000 pg/mL). Pharmaco-
kinetic parameters of the test proteins were determined by Drug
and Statistics Software (DAS, Version 2.0; Mathematical Phar-
macology Professional Committee of China). The elimination half-
life (t1/2) was calculated using the formula t1/2=0.693/Ke (Ke
stands for elimination rate constant).
Evaluation of Hepatoprotective Effect of Solid-Phase
PEGylated rhKGF-1 Using a Rat Model of Acute Liver
Failure
48 male SD rats were randomly divided into four groups (12
rats/group): enalpril interventional group A (rhKGF-1-pretreated
groups), enalpril interventional group B (PEGylated rhKGF-1-
pretreated groups), injury-model group and healthy control group.
Rats in interventional groups were injected intraperitoneally with
either rhKGF-1 or PEGylated rhKGF-1 with a dose of 0.1 mmol/
kg. This optimized dose was obtained from our preliminary animal
experiments. Rats in the injury-model and control groups were
injected intraperitoneally with normal saline. After 24 hours, rats
in the test and the injury-model groups were injected intraperi-
toneally with 2.5 mL/kg CCl4 (Kanto Chemistry, Tokyo, Japan)
dissolved in olive oil (Kanto Chemistry, Tokyo, Japan), and rats in
control group received normal saline injection again. 4 hour after
intoxication, all rats were sacrificed and then the levels of AST and
ALT were determined in their serum using full automatic
biochemical analyzer as reported previously [48].
Statistical Analysis of the Experimental Data
The in vitro experiments were performed three times with
triplicate samples for each individual experiment. All data were
expressed as mean 6 SD and subjected to statistical analysis by
ANOVA and student t-test using statistical software NASDAQ:
SPSS from SPSS Inc.
Supporting Information
Figure S1 SDS-PAGE and CD analysis of Mal-PEGylated
rhKGF-1. Panel A. SDS-PAGE analysis of solution-phase Mal-
PEGylation of rhKGF-1 in the absence or presence of 2 M urea.
Lane M, molecular weight standards; lanes a and b correspond to
the PEGylation reaction mixtures in the absence of 2 M urea;
lanes c and d correspond to the PEGylation reaction mixtures in
the presence of 2 M urea. Panel B. Far-UV CD spectra of non-
PEGylated (black line), solid-phase PEGylated rhKGF-1 (red line)
and solution-phase Mal-PEGylated rhKGF-1 (blue line). The
ellipticities are reported as mean residue ellipticity (MRE) (deg
cm2 dmol-1). Panel C. Ribbon presentation of KGF-1 structure.
Amino (N) and carboxyl (C) terminal ends are indicated, the Cys
40 is also labeled.
(DOC)
Figure S2 SDS-PAGE analysis of the solution-phase Alk-
PEGylated rhKGF-1. Lane M, molecular weight standards;
lane a, non-PEGylated rhKGF-1; lane b, solid-phase PEGylated
product achieved at reaction time of 8 h and PEG PEG-to-protein
molar ratio of 10; lane c–f, PEGylation products obtained at
reaction time of 8 h and PEG-to-protein molar ratio of 5, 10, 15
and 20, respectively.
(DOC)
Figure S3 Elution profile of the solid-phase Alk-PEGyla-
tion mixture from Heparin-Sepharose column.
(DOC)
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